19419 related articles for article (PubMed ID: 12721281)
1. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
3. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
4. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
5. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
6. Enhancing communication among data monitoring committees and institutional review boards.
Taylor HA; Chaisson L; Sugarman J
Clin Trials; 2008; 5(3):277-82. PubMed ID: 18559418
[TBL] [Abstract][Full Text] [Related]
7. Exception from informed consent: viewpoint of institutional review boards--balancing risks to subjects, community consultation, and future directions.
Ernst AA; Fish S
Acad Emerg Med; 2005 Nov; 12(11):1050-5. PubMed ID: 16264073
[TBL] [Abstract][Full Text] [Related]
8. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
9. A clinical trial primer: historical perspective and modern implementation.
Karsh LI
Urol Oncol; 2012; 30(4 Suppl):S28-32. PubMed ID: 22795078
[TBL] [Abstract][Full Text] [Related]
10. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
11. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Patel JD; Krilov L; Adams S; Aghajanian C; Basch E; Brose MS; Carroll WL; de Lima M; Gilbert MR; Kris MG; Marshall JL; Masters GA; O'Day SJ; Polite B; Schwartz GK; Sharma S; Thompson I; Vogelzang NJ; Roth BJ
J Clin Oncol; 2014 Jan; 32(2):129-60. PubMed ID: 24327669
[TBL] [Abstract][Full Text] [Related]
12. [The origin of informed consent].
Mallardi V
Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
[TBL] [Abstract][Full Text] [Related]
13. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
14. Practical guide to understanding clinical research compliance.
Neely JG; Paniello RC; Graboyes EM; Sharon JD; Grindler DJ; Nussenbaum B
Otolaryngol Head Neck Surg; 2014 May; 150(5):716-21. PubMed ID: 24598406
[TBL] [Abstract][Full Text] [Related]
15. Journalists, district attorneys and researchers: why IRBs should get in the middle.
Chodos AH; Lee SJ
BMC Med Ethics; 2015 Mar; 16():19. PubMed ID: 25889147
[TBL] [Abstract][Full Text] [Related]
16. Federal commissions and local IRBs.
Yesley MS
Hastings Cent Rep; 1983 Oct; 13(5):11-2. PubMed ID: 6643032
[TBL] [Abstract][Full Text] [Related]
17. Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology.
Brandon TH; Goniewicz ML; Hanna NH; Hatsukami DK; Herbst RS; Hobin JA; Ostroff JS; Shields PG; Toll BA; Tyne CA; Viswanath K; Warren GW
J Clin Oncol; 2015 Mar; 33(8):952-63. PubMed ID: 25572671
[TBL] [Abstract][Full Text] [Related]
18. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
Bramstedt KA; Kassimatis K
Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
[TBL] [Abstract][Full Text] [Related]
19. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
Zon R; Meropol NJ; Catalano RB; Schilsky RL
J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
